Resmetirom(1) is the first FDA-approved drug for the treatment of non-alcoholic steatohepatitis(NASH) in 2024. It is primarily used in clinical settings to address stage F2 and F3 liver fibrosis associated with non-alcoholic steatohepatitis. The drug exhibits favorable safety and efficacy, thereby generating substantial market demand. Consequently, investigating a synthesis method suitable for industrial-scale production of 1 holds immense significance. 6-(4-Amino-2,6-dichlorophenoxy)-4- isopropylpyridazin-3(2H)-one(2) is a key intermediate for the synthesis of 1 . This review summarizes the strategies and specific feasible synthetic routes of key intermediate 2 and the target product 1 , providing a reference for the research of its synthesis process.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |